What were the main drivers of Johnson & Johnson's sales growth in the first quarter of 2003?

Sales growth was driven by a broad-based increase across all three segments: Consumer, Pharmaceutical, and Medical Devices & Diagnostics. Key product performances mentioned include NEUTROGENA and SPLENDA in Consumer, REMICADE, RISPERDAL, DURAGESIC, and TOPAMAX in Pharmaceutical, and DePuy's orthopaedics and Ethicon's surgical products in Medical Devices & Diagnostics. International sales also contributed significantly, boosted by favorable currency exchange rates.

Can you detail the recent acquisitions and their expected impact?

Johnson & Johnson completed several acquisitions in Q1 2003: Orquest, Inc. (biotechnology for orthopaedics), Orapharma, Inc. (specialty pharmaceuticals like ARESTIN), and 3-Dimensional Pharmaceuticals, Inc. (early-stage drug development). Looking ahead, the company expects substantial pre-tax charges for In-Process Research & Development (IPR&D) in Q2 2003, ranging from $700-$800 million for the Scios, Inc. acquisition and approximately $175 million for the Link Spine Group, Inc. acquisition.

Are there any significant legal proceedings or contingent liabilities that investors should be aware of?

The company is involved in numerous legal proceedings, most notably a large number of product liability cases concerning the drug PROPULSID, which was withdrawn from the market. While the company is vigorously defending these claims and believes its insurance and reserves will cover liabilities, the ultimate outcome is uncertain and could have a significant impact on earnings in a given period. Additionally, patent litigation related to key products like coronary stents and generic drug challenges are ongoing.

How did the company's financial position and cash flow performance look in Q1 2003?

The company demonstrated strong liquidity, with cash and marketable securities totaling $7.8 billion. Operating cash flow was robust at $2.0 billion, supporting investments in capital expenditures, acquisitions, and shareholder returns. Total assets grew by 3.5% to $41.9 billion, and shareholders' equity per share increased to $8.10. Debt levels remained well-managed, representing 14.6% of total capital.

JNJ 10-Q Quarterly Report Q1 FY2003 — Revenue, Net Income, EPS

Summary

Johnson & Johnson (JNJ) reported strong first-quarter 2003 results, with worldwide sales increasing by 12.3% to $9.8 billion, driven by robust performance across its Consumer, Pharmaceutical, and Medical Devices & Diagnostics segments. Net earnings rose 12.9% to $2.1 billion, or $0.69 per diluted share, reflecting a 16.9% increase from the prior year's first quarter. The company also demonstrated effective management of its financial resources, with operating cash flow of $2.0 billion and a continued commitment to shareholder returns through an increased dividend, marking the 41st consecutive annual increase. The company strategically expanded its portfolio through several key acquisitions, including those of Orquest, Inc., Orapharma, Inc., and 3-Dimensional Pharmaceuticals, Inc., all aimed at enhancing its pipeline in areas like orthopaedics, specialty pharmaceuticals, and early-stage drug development for cardiovascular and inflammatory diseases. Significant forward-looking investments were made in anticipation of new product launches, such as the CYPHER drug-eluting stent, with substantial R&D charges expected in the second quarter related to the acquisition of Scios, Inc.

Key Highlights

1Worldwide sales grew 12.3% to $9.8 billion in Q1 2003, with international sales up 18.2% (11.3% from currency).
2Net earnings increased 12.9% to $2.1 billion, resulting in a 16.9% rise in diluted EPS to $0.69.
3Operating cash flow was strong at $2.0 billion for the quarter.
4The company declared a regular cash dividend of $0.24 per share, a 17.1% increase, marking the 41st consecutive annual dividend increase.
5Strategic acquisitions were made, including Orquest, Orapharma, and 3-Dimensional Pharmaceuticals, bolstering the company's innovation pipeline.
6Significant R&D charges are anticipated in Q2 2003 related to the acquisition of Scios, Inc. ($700-800 million pre-tax) and Link Spine Group, Inc. ($175 million pre-tax).
7The CYPHER drug-eluting coronary stent received FDA approval and began shipping, aiming to reduce restenosis.

JOHNSON & JOHNSON Quarterly Report (Amendment) for Q1 Ended Mar 30, 2003

Summary

Key Highlights

Frequently Asked Questions